Disc Medicine price target raised to $73 from $70 at Scotiabank

Scotiabank analyst Greg Harrison raised the firm’s price target on Disc Medicine (IRON) to $73 from $70 and keeps an Outperform rating on the shares. The company has significantly decreased the regulatory and clinical risk of bitopertin, with plans to submit a new drug application under the FDA’s accelerated pathway in 2H of 2025, the analyst tells investors. Additionally, bitopertin is “well-positioned” to become the standard of care in erythropoietic protoporphyria and X-linked protoporphyria, the firm adds. Scotiabank is adjusting its price target on the stock to reflect updated launch timing.